Table 2.
One-way sensitivity analysis: effect of varying the price of each cost component by ±25% on total costs of treating CSU
| Cost component | ± Change in total treatment costs, USD
|
|||
|---|---|---|---|---|
| ±25% change in price
|
±25% change in utilization
|
|||
| Before | After | Before | After | |
| Omalizumab | NAa | 3,840,210 | NAa | NAb |
| Outpatient visits | 751,334 | 79,781 | 751,334 | 79,781 |
| Conventional drugs | 69,845 | 7,491 | 12,220 | 7,491 |
| ER visits | 63,914 | 1,911 | 63,914 | 1,911 |
| Diagnostic tests | 26,007 | 26,007 | NAb | NAb |
Notes:
a
Omalizumab was not used in the “Before” period.
b
All patients were given diagnostic testing and, in the “After” period, omalizumab; so it was not relevant to vary utilization of these factors.
Abbreviations: CSU, chronic spontaneous urticaria; USD, US dollars; ER, emergency room; NA, not applicable.